These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1669172)

  • 1. [Changes in levels of electrolytes in serum of patients with allogenic bone marrow transplants].
    Ratajczak MZ; Jedrzejczak WW
    Pol Tyg Lek; 1991 Oct 28-Nov 4; 46(43-44):829-33. PubMed ID: 1669172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of destruction and regeneration of the haemopoietic system after administration of busulphan and cyclophosphamide followed by bone marrow transplantation. Peripheral blood parameters.
    Szczylik C; Ratajczak MZ; Urbanowska E; Jedrzejczak WW
    Acta Med Pol; 1989; 30(3-4):93-109. PubMed ID: 2519630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic myelogenous leukemia with allogeneic bone marrow transplantation after preparation with busulfan and cyclophosphamide (BuCy2): an update.
    Brodsky I; Biggs JC; Szer J; Crilley P; Atkinson K; Downs K; Dodds A; Concannon AJ; Avalos BR; Tutschka P
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):27-31; quiz 32. PubMed ID: 8342072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children.
    Shaw PJ; Hugh-Jones K; Hobbs JR; Downie CJ; Barnes R
    Bone Marrow Transplant; 1986 Dec; 1(2):193-200. PubMed ID: 3332132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children.
    Hobbs JR; Hugh-Jones K; Shaw PJ; Downie CJ; Williamson S
    Bone Marrow Transplant; 1986 Dec; 1(2):201-8. PubMed ID: 2971409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of IL-18 and sIL2R on aGVHD occurrence after hematopoietic stem cell transplantation in some Iranian patients.
    Shaiegan M; Iravani M; Babaee GR; Ghavamzadeh A
    Transpl Immunol; 2006 Jan; 15(3):223-7. PubMed ID: 16431290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow transplantation following busulfan and cyclophosphamide for acute myelogenous leukemia.
    Crilley P; Topolsky D; Bulova S; Bigler R; Brodsky I
    Bone Marrow Transplant; 1990 Mar; 5(3):187-91. PubMed ID: 2331539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I-II study of busulfan and cyclophosphamide conditioning for transplantation in advanced multiple myeloma.
    Schiller G; Nimer S; Vescio R; Lieb G; Lee M; Gajewski J; Territo M; Berenson J
    Bone Marrow Transplant; 1994 Jul; 14(1):131-6. PubMed ID: 7951100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes of certain parameters of renal function in patients with allogenic bone marrow transplantation].
    Ratajczak MZ; Szczylik C; Jedrzejczak WW
    Pol Tyg Lek; 1991 Oct 7-21; 46(40-42):764-9. PubMed ID: 1669154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic bone marrow transplantation for hematological malignancies following therapy with high doses of busulphan and cyclophosphamide.
    Angelucci E; Polchi P; Lucarelli G; Galimberti M; Baronciani D; Giardini C; Durazzi SM; Moretti L; Donati M
    Haematologica; 1989; 74(5):455-61. PubMed ID: 2511115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. The BMT Team.
    Kanda Y; Akiyama H; Tanikawa S; Sakamaki H; Sasaki T; Takamoto S; Onozawa Y
    Am J Hematol; 1996 Apr; 51(4):265-8. PubMed ID: 8602625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of high-dose busulphan and cyclophosphamide as conditioning therapy for allogeneic bone marrow transplantation in adults with haematological malignancies.
    Bandini G; Belardinelli A; Rosti G; Calori E; Motta MR; Rizzi S; Benini C; Tura S
    Bone Marrow Transplant; 1994 May; 13(5):577-81. PubMed ID: 8054910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary results of high-dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue.
    Lu C; Braine HG; Kaizer H; Saral R; Tutschka PJ; Santos GW
    Cancer Treat Rep; 1984 May; 68(5):711-7. PubMed ID: 6373004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation.
    Copelan EA; Penza SL; Elder PJ; Ezzone SA; Scholl MD; Bechtel TP; Belt PS; Avalos BR
    Bone Marrow Transplant; 2000 Jun; 25(12):1219-22. PubMed ID: 10871724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allogeneic bone marrow transplantation from HLA-identical siblings following conditioning with busulphan and cyclophosphamide.
    Wiktor-Jedrzejczak W; Szczylik C; Matej H; Pojda Z; Ratajczak MZ; Myc A; Siekierzyński M; Kansy J; Kłos M; Rybicki Z
    Arch Immunol Ther Exp (Warsz); 1991; 39(4):441-7. PubMed ID: 1821620
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning.
    Mehta J; Powles RL; Mitchell P; Rege K; De Lord C; Treleaven J
    Bone Marrow Transplant; 1994 May; 13(5):583-7. PubMed ID: 8054911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Busulfan-containing pre-transplant regimens for the treatment of solid tumors.
    Ghalie R; Reynolds J; Valentino LA; Manson S; Korenblit AD; Feingold JM; Adler SS; Pruett J; Kaizer H
    Bone Marrow Transplant; 1994 Sep; 14(3):437-42. PubMed ID: 7994269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.